Invitrogen™ ELISA Kit for Human LAG-3

Ref.: BL-RE-096826Manufacturer ref.: BMS2211 96 Tests
€716.00 excl. VAT

L-ELISA for the human lymphocyte activation gene 3 (human LAG-3) (CD223) quantifies human LAG-3 in serum, plasma, buffered solution or human cell culture medium. The test will recognize exclusively the LAG-3 Hu...

Accession number
P18627
Dose range
6.2-400 pg/ml
Sensitivity of the dosage
2.20 pg/ml
Conjugate
Biotin
Product type
Kit ELISA
Brand
Invitrogen

L-ELISA for the human lymphocyte activation gene 3 (human LAG-3) (CD223) quantifies human LAG-3 in serum, plasma, buffered solution or human cell culture medium. The test will recognize exclusively the LAG-3 Hu...

L-ELISA for the human lymphocyte activation gene 3 (human LAG-3) (CD223) quantifies human LAG-3 in serum, plasma, buffered solution or human cell culture medium. The test will only recognize natural and recombinant LAG-3 Hu. Method Principle The human LAG-3 solid phase ELISA sandwich test (immuno-enzymatic test) is designed to measure the amount of the target bound between a pair of matched antibodies. A target-specific antibody was pre-vested in the wells of the supplied microplate. Samples, standards or controls are then added to these wells and bound to immobilized antibody (capture). The sandwich is formed by adding the second antibody (detector), a substrate solution that reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this coloured product is directly proportional to the concentration of TP (p) present in the original sample. Rigorous validation Each batch manufactured from this ELISA kit is tested for quality for criteria such as sensitivity, specificity, accuracy and batch-to-batch consistency. See the product manual for more information on validation.

CD-223 protein (LAG-3, lymphocyte activation protein 3) is a 70 kDa surface glycoprotein in the Ig superfamily. CD-223 binds to Class II MHC with higher affinity than CD4. It is also considered to be involved in the negative regulation of T cell activation and homeostatic proliferation. The surface expression of CD-223 was reported on activated T cells (including regulatory T cells) and NK lymphocytes. CD8+ T cells generally express CD-223 at significantly higher levels than CD4+ T cells. Coexpression of CD-223 and CD49b has been proposed to identify T-cells that regulate type 1 (Tr1 cells) in humans and mice. The LAG-3 protein contains 4 extracellular domains similar to Ig; its gene contains 8 exons. Sequence data, exon/intron organization and chromosome localization all indicate the homology of CD-223 to CD4.

Sensitivity

Sensitivity of the dosage: 2.20 pg/ml.

Measurement range

Dose range: 6.2-400 pg/ml.

Duration of dosing

Total duration of dosing: 3 h 30 min.

Reproducibility

Coefficient of intra-dose variation 5.8%, inter-dose 6.9%.

Target

Target: Human.

Technical specifications

General
BrandInvitrogen
Supplier ref. (Fisher Scientific)15991087
Specifications
Accession numberP18627
Dose range6.2-400 pg/ml
Sensitivity of the dosage2.20 pg/ml
ConjugateBiotin
Product typeKit ELISA
Type of sampleSerum, Surnatant, Supernatant
Target speciesHuman
For use with (equipment)Colorimetric microplate reader
Genetic identification (Enter)3902
Gene symbol(s)CD223
Coefficient of inter-dose variation6.9%
Coefficient of intra-dose variation5.8%
Contents of kitsPre-coated well plate 96, Standard, sample diluent, dosing buffer concentrate, biotinylated detection antibodies, SAV-HRP, washing pad, chromogen, stop solution, adhesive film for plates
Marker or dyeHRP
Quantity96 Tests
Regulatory statusRUO
TargetHuman
Test time1 h 20 min
Physical characteristics
Volume of samplePlasma, 10 μl; serum, 10 μl; supernatant, 10 μl
Storage and shipping
Storage conditions2°C to 8°C
Total duration of dosing3 h 30 min

Origin and customs

Manufacturer ref.BMS2211
Country of originAutriche
HS customs code3002 15 00 00
A question or a specific configuration?
Contact us for a quote.